Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 20:42 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
8-Chloroadenosine in Combination With Venetoclax for the Treatment of Patients With Relapsed/Refractory Acute Myeloid Leukemia
NCT05263284 · City of Hope Medical Center · PHASE1 · suspended · last registry update 2026-10-20 · Acute myeloid leukemia · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Safety Issues, status is being updated per PI due to safety issues. Study is now Temporarily Closed to Accrual.” | – | Registry record, City of Hope Medical Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against BCL2 in acute myeloid leukemia within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-10-20Also stopped (suspended): City of Hope Medical Center, Azacitidine + Regorafenib (NCT06454409)
- 2026-10-20Also stopped (suspended): City of Hope Medical Center, Decitabine + Pembrolizumab (NCT03969446)
- 2026-10-19Results posted on the registry: Sanofi, SAR443579 + venetoclax (NCT06508489)
- 2026-10-19Also stopped (terminated): Sanofi, SAR443579 + venetoclax (NCT06508489)
- 2026-10-16Also stopped (terminated): M.D. Anderson Cancer Center, Azacitidine + Venetoclax (NCT04062266)
- 2026-10-06Results posted on the registry: National Cancer Institute (NCI), Cytarabine + Daunorubicin (NCT04817241)
- 2026-10-01Also stopped (terminated): Bristol-Myers Squibb, BMS-986497 + Azacitidine (NCT06419634)
- 2026-10-01Also stopped (suspended): Institut Paoli-Calmettes, Dasatinib (NCT06055621)
- 2026-08-25Also stopped (suspended): National Cancer Institute (NCI), Azacitidine + Iadademstat (NCT06514261)
- 2026-08-24Also stopped (suspended): National Cancer Institute (NCI), Decitabine and Cedazuridine + Venetoclax (NCT06802523)
- 2026-08-24Also stopped (terminated): University of Michigan Rogel Cancer Center, Venetoclax + FLAG or CLAG Protocol (NCT05780879)
- 2026-08-05Also stopped (withdrawn): Memorial Sloan Kettering Cancer Center, Azacitidine (AZA) + Venetoclax (NCT06903702)
- 2026-07-29Phase 3 first posted: Ruijin Hospital, Mitoxantrone Hydrochloride Liposome + Cytarabine (NCT07735117)
- 2026-07-20Phase 3 first posted: The Second Affiliated Hospital of Kunming Medical University, a drug against BCL2 (NCT07712848)
- 2026-07-13Also stopped (terminated): Antonio M Jimenez Jimenez, Venetoclax + Azacitidine (NCT06158100)
- 2026-06-11Results posted on the registry: University of Colorado, Denver, Azacitidine + Venetoclax (NCT03573024)
- 2026-06-04Results posted on the registry: AbbVie, Venetoclax + Azacitidine (NCT04161885)
- 2026-06-04Also stopped (terminated): AbbVie, Venetoclax + Azacitidine (NCT04161885)
- 2026-06-03Phase 3 first posted: Ipsen, IPN60340 + azacitidine + venetoclax + Placebo + azacitidine + venetoclax (NCT07623187)
- 2026-05-13Phase 3 first posted: The First Affiliated Hospital of Soochow University, VaBU (NCT07583888)
- 2026-05-12Phase 3 first posted: AbbVie, Pivekimab Sunirine + Venetoclax (NCT07581002)
- 2026-04-23Results posted on the registry: M.D. Anderson Cancer Center, Azacitidine + Magrolimab (NCT04435691)
- 2026-04-23Also stopped (terminated): M.D. Anderson Cancer Center, Azacitidine + Magrolimab (NCT04435691)
- 2026-04-20Phase 3 first posted: Institute of Hematology & Blood Diseases Hospital, China, Venetoclax + Azacitidine (NCT07539818)
- 2026-04-17Phase 3 first posted: Guangdong Second Provincial General Hospital, Ventoclax + Cytarabine (NCT07537257)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision